Request Demo
Last update 29 Nov 2025
BA-2101
Last update 29 Nov 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms anti-IL4R antibody(Shandong Boan Biotech), BA-2101, BA2101 + [2] |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with BA-2101CTR20230119
在健康受试者中评价BA2101单次皮下注射的安全性、耐受性、药代动力学、药效学及免疫原性的随机、双盲、安慰剂对照、剂量递增的Ⅰ期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalating Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of a single subcutaneous injection of BA2101 in healthy subjects
CTR20242602
在中重度特应性皮炎患者中评价BA2101多次给药的安全性、耐受性、药代动力学、药效学、免疫原性及初步疗效的II期临床研究
[Translation] A Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of multiple doses of BA2101 in patients with moderate to severe atopic dermatitis
100 Clinical Results associated with BA-2101
Login to view more data
100 Translational Medicine associated with BA-2101
Login to view more data
100 Patents (Medical) associated with BA-2101
Login to view more data
100 Deals associated with BA-2101
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 2 | China | 19 Jul 2024 | |
| Severe Atopic Dermatitis | Phase 2 | China | 19 Jul 2024 | |
| Asthma | Phase 2 | China | - | |
| Pruritus | Phase 2 | China | - | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | China | - | |
| Sinusitis | Phase 2 | China | - | |
| Urticaria | Phase 2 | China | - | |
| Chronic Urticaria | Phase 1 | China | 09 Feb 2023 | |
| prurigo nodularis | Phase 1 | China | 09 Feb 2023 | |
| Chronic rhinosinusitis with nasal polyps | IND Approval | China | 22 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free